A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)

NCT06817343 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular (Wet) Age-related Macular Degeneration (AMD)

Interventions

BIOLOGICAL: Aflibercept (2.0 mg)

Sponsor

Exegenesis Bio